Table 2.
Psoriasis outcomes after 12 and 60 weeks in each study
| Induction period, Week 12 | Open-label ixekizumab treatment, Week 60 | |||||||
|---|---|---|---|---|---|---|---|---|
| UNCOVER-2 | UNCOVER-3 | UNCOVER-2 (sPGA 0/1 NR) | UNCOVER-3 (PASI 75 NR) | |||||
| PBO (N = 168) | ETN (N = 358) | PBO (N = 193) | ETN (N = 382) | PBO/ IXEQ4W (N = 155) |
ETN/ IXEQ4W (N = 200) |
PBO/ IXEQ4W (N = 169) |
ETN/ IXEQ4W (N = 165) |
|
| sPGA 0/1 (NRI), n (%) | 4 (2.4) | 129 (36.0) | 13 (6.7) | 159 (41.6) | 112 (72.3) | 142 (71.0) | 132 (78.1) | 114 (69.1) |
| PASI 75 (NRI), n (%) | 4 (2.4) | 149 (41.6) | 14 (7.3) | 204 (53.4) | 129 (83.2) | 165 (82.5) | 147 (87.0) | 128 (77.6) |
| PASI 90 (NRI), n (%) | 1 (0.6) | 67 (18.7) | 6 (3.1) | 98 (25.7) | 109 (70.3) | 137 (68.5) | 133 (78.7) | 112 (67.9) |
| PASI 100 (NRI), n (%) | 1 (0.6) | 19 (5.3) | 0 | 28 (7.3) | 70 (45.2) | 87 (43.5) | 93 (55.0) | 71 (43.0) |
| NAPSI = 0 (NRI), n (%)a | 10 (8.8) | 24 (10.5) | 5 (4.3) | 24 (10.2) | 57 (53.3) | 58 (45.0) | 65 (60.7) | 50 (49.5) |
| PSSI = 0 (NRI), n (%)b | 11 (7.3) | 144 (44.7) | 16 (9.1) | 178 (51.1) | 103 (73.0) | 130 (71.4) | 130 (83.9) | 111 (74.5) |
| Change from baseline PASI (LOCF)c | −0.9 (0.5) | −11.6 (0.3) | −3.1 (0.4) | −14.5 (0.3) | −19.1 (8.5) | −16.4 (8.1) | −19.6 (8.9) | −18.2 (9.1) |
| % Improvement from baseline PASI (LOCF)c | 6.8 (2.1) | 58.9 (1.5) | 14.1 (1.8) | 68.8 (1.3) | 92.5 (17.2) | 88.2 (37.9) | 93.0 (17.1) | 87.2 (23.4) |
ETN etanercept, ETN-NR/IXEQ4W etanercept Weeks 0–12, placebo at Week 12, and ixekizumab every 4 weeks for Weeks 16–60, LOCF last observation carried forward, NAPSI nail psoriasis severity index, NR non-responder, NRI non-responder imputation, PASI psoriasis area and severity index, PBO placebo, PBO-NR/IXEQ4W placebo Weeks 0-12 and ixekizumab every 4 weeks for Weeks 16–60 after a starting dose of 160 mg at Week 12, PSSI psoriasis scalp severity index, sPGA static physician global assessment
aOnly patients with NAPSI >0 at baseline were included in this analysis
bOnly patients with PSSI >0 at baseline were included in this analysis
cWeek 12 results are reported as least squares (LS) mean (standard error) and Week 60 results are reported as LS mean (standard deviation)